Singhal to lead development at Biogen as company splits R&D
Plus: Baumal named CMO at Apellis, and updates from Pheast, Sofinnova Partners, GE, Lexeo and more
Biogen Inc. (NASDAQ:BIIB) said Head of Global Safety and Regulatory Sciences and Interim Head of R&D Priya Singhal would become EVP, head of development — an appointment that comes after the company’s decision to separate research and development into two distinct functions. Singhal, who has led R&D since Alfred Sandrock’s retirement at YE21, will continue to serve as interim head of research as the company seeks an EVP to take the job. Both roles report to Chris Viehbacher, who was recently made CEO.
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) hired Caroline Baumal as CMO, replacing Federico Grossi who will remain at the company until Feb. 23. Baumal is professor of ophthalmology at Tufts Medical Center. Apellis’ geographic atrophy therapy has a PDUFA date of Feb. 26. ...